Patents-Review.com
ClassID:

110012 ⎘

C12N2710/24121 - CPC Classification

Classification description:

dsDNA viruses; Details; Poxviridae; Orthopoxvirus, e.g. vaccinia virus, variola Viruses as such, e.g. new isolates, mutants or their genomic sequences

Recent Application in this class:
#1
20260139233
2026-05-21

SYNTHETIC CHIMERIC POXVIRUSES

 #2
20260022350
2026-01-22

SYNTHETIC CHIMERIC POXVIRUSES

 #3
20250297002
2025-09-25

BISPECIFIC T-CELL ENGAGER, RECOMBINANT ONCOLYTIC VIRUS THEREOF, AND USE THEREOF

 #4
20250177518
2025-06-05

RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS

 #5
20250084384
2025-03-13

CHIMERIC POXVIRUS COMPOSITIONS AND USES THEREOF

 #6
20240229069
2024-07-11

MODIFIED ORTHOPOXVIRUS VECTORS

 #7
20240132913
2024-04-25

MODIFIED ORTHOPOXVIRUS VECTORS

 #8
20230346863
2023-11-02

Immuno-modulated replication-efficient Vaccinia virus strain

 #9
20230310526
2023-10-05

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

 #10
20230293608
2023-09-21

Oncolytic Vaccinia Virus

 #11
20230086531
2023-03-23

METHODS OF MANUFACTURING ACTIVATED IMMUNE CELLS

 #12
20230057304
2023-02-23

Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

 #13
20230008089
2023-01-12

Immuno-Oncolytic Therapies

 #14
20230008052
2023-01-12

CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF

 #15
20230002741
2023-01-05

SYNTHETIC CHIMERIC POXVIRUSES

 #16
20230002740
2023-01-05

VARIANT ONCOLYTIC VACCINIA VIRUS AND METHODS OF USE THEREOF

 #17
20220347244
2022-11-03

RECOMBINANT VACCINIA VIRUS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

 #18
20220339221
2022-10-27

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

 #19
20220290179
2022-09-15

GENETICALLY ENGINEERED ONCOLYTIC VACCINIA VIRUSES AND METHODS OF USES THEREOF

 #20
20220275347
2022-09-01

ONCOLYTIC VACCINIA VIRUS

 #21
20220267713
2022-08-25

METHOD FOR PRODUCING VIRUS AND HARVEST LIQUID COMPOSITION

 #22
20220220505
2022-07-14

Producer Viruses for Generation of Retroviruses In Situ

 #23
20220186192
2022-06-16

Vaccinia virus mutants useful for cancer immunotherapy

 #24
20220064672
2022-03-03

ENGINEERED ONCOLYTIC VIRUSES EXPRESSING PD-L1 INHIBITORS AND USES THEREOF

 #25
20220056481
2022-02-24

M2-DEFECTIVE POXVIRUS

 #26
20220056480
2022-02-24

MODIFIED ORTHOPOXVIRUS VECTORS

 #27
20220049228
2022-02-17

Modified Extracellular Enveloped Virus

 #28
20210009965
2021-01-14

Engineered vaccinia virus

 #29
20200392535
2020-12-17

Modified orthopoxvirus vectors

 #30
20200376051
2020-12-03

Immuno-modulated replication-efficient vaccinia virus strain

 #31
20200339959
2020-10-29

Vaccinia virus mutants useful for cancer immunotherapy

 #32
20200316198
2020-10-08

Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

 #33
20200289591
2020-09-17

Isolated Recombinant Oncolytic Poxvirus, Pharmaceutical Composition, and Use Thereof in Treatment of Tumors and/or Cancer

 #34
20200237839
2020-07-30

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy

 #35
20200216562
2020-07-09

Integral membrane protein display on poxvirus extracellular enveloped virions

 #36
20200197457
2020-06-25

Oncolytic virus for expression of immune checkpoint modulators

 #37
20200165577
2020-05-28

Stable virus-containing composition

 #38
20190367887
2019-12-05

Vaccinia virus vectors related to MVA with extensive genomic symmetries

 #39
20190367886
2019-12-05

METHOD FOR PRODUCING VACCINIA VIRUS EXPRESSING FOREIGN GENE

 #40
20190276556
2019-09-12

Integral membrane protein display on poxvirus extracellular enveloped virions

 #41
20190247487
2019-08-15

Recombinant vaccinia virus and use thereof

 #42
20190218522
2019-07-18

Chimeric poxvirus compositions and uses thereof

 #43
20190183947
2019-06-20

Oncolytic vaccinia virus mutants and using same for cancer treatment

 #44
20190112388
2019-04-18

Integral membrane protein display on poxvirus extracellular enveloped virions

 #45
20190055582
2019-02-21

Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity

 #46
20190054131
2019-02-21

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

 #47
20190046640
2019-02-14

Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

 #48
20190000899
2019-01-03

Anti-cancer oncolytic virus combination therapies and elite responder selection platforms

 #49
20180251736
2018-09-06

Synthetic chimeric poxviruses

 #50
20180195050
2018-07-12

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #51
20180028635
2018-02-01

COMPOSITION AND USES THEREOF

 #52
20170157188
2017-06-08

Oncolytic virus for expression of immune checkpoint modulators

 #53
20170128561
2017-05-11

Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus

 #54
20170081642
2017-03-23

RECOMBINANT POXVIRUS VECTOR COMPRISING TETANUS TOXIN FRAGMENT C

 #55
20170020938
2017-01-26

Oncolytic Vaccinia Virus

 #56
20160281066
2016-09-29

Mitogen-activated protein kinase-dependent recombinant vaccinia virus (MD-RVV) and use thereof

 #57
20160235793
2016-08-18

Immuno-oncolytic therapies

 #58
20160144011
2016-05-26

Composition and uses thereof

 #59
20160108371
2016-04-21

Recombinant vaccinia virus derived from KVAC103 strain

 #60
20160106829
2016-04-21

Attenuated vaccinia virus KVAC103 strain

 #61
20160040135
2016-02-11

Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites

 #62
20160010064
2016-01-14

Mutant vaccinia virus strains, uses thereof and method of producing the same

 #63
20160000842
2016-01-07

ONCOLYTIC VIRUS

 #64
20150359871
2015-12-17

Immunogenic compositions comprising silicified virus and methods of use

 #65
20150299666
2015-10-22

MVA virus and uses thereof

 #66
20150275186
2015-10-01

Production of viral vaccines in suspension on avian embryonic derived stem cell lines

 #67
20150175976
2015-06-25

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #68
20150017126
2015-01-15

Poxviral oncolytic vectors

 #69
20140234257
2014-08-21

Oncolytic viruses and methods for treating neoplastic disorders

 #70
20130183271
2013-07-18

Methods and compositions concerning poxviruses and cancer

 #71
20120328650
2012-12-27

MODIFIED VACCINIA ANKARA VIRUS VARIANT

 #72
20120308995
2012-12-06

Vaccinia virus mutants containing the major genomic deletions of MVA

 #73
20120308484
2012-12-06

Clonal strains of attenuated vaccinia viruses and methods of use thereof

 #74
20120263750
2012-10-18

Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites

 #75
20120238001
2012-09-20

Production of viral vaccines in suspension on avian embryonic derived stem cell lines

 #76
20120114612
2012-05-10

Oncolytic viruses and methods for treating neoplastic disorders

 #77
20110293527
2011-12-01

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #78
20110236976
2011-09-29

Vector comprising multiple homologous nucleotide sequences

 #79
20110182933
2011-07-28

Modified virus variant

 #80
20110182932
2011-07-28

Modified Vaccinia Ankara virus variant

 #81
20100119545
2010-05-13

Modified Vaccinia Ankara virus variant

 #82
20090169579
2009-07-02

Modified Vaccinia Ankara virus variant

 #83
20090155287
2009-06-18

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #84
20090098529
2009-04-16

Methods for attenuating virus strains for diagnostic and therapeutic uses

 #85
20090081251
2009-03-26

Production of viral vaccines in suspension on avian embryonic derived stem cell lines

 #86
20090053244
2009-02-26

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

 #87
20090004723
2009-01-01

Methods and compositions concerning poxviruses and cancer

 #88
20080089907
2008-04-17

Modified Vaccinia Ankara virus variant

 #89
20060280758
2006-12-14

Modified Vaccinia Ankara virus variant

 #90
20060099224
2006-05-11

Methods and compositions concerning poxviruses and cancer

 #91
20050271688
2005-12-08

Modified Vaccinia Ankara virus variant